APA (7th ed.) Citation

R, D., S, S., Jr, M. W., MO, B., MH, T., L, H., . . . PA, A. (2026). Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma. Future oncology (London, England), 22(9), 995. https://doi.org/10.1080/14796694.2026.2643481

Chicago Style (17th ed.) Citation

R, Dummer, et al. "Plain Language Summary of the LOGIC 2 Study: Encorafenib, Binimetinib, Plus a Third Drug for People with BRAF V600-mutant Melanoma." Future Oncology (London, England) 22, no. 9 (2026): 995. https://doi.org/10.1080/14796694.2026.2643481.

MLA (9th ed.) Citation

R, Dummer, et al. "Plain Language Summary of the LOGIC 2 Study: Encorafenib, Binimetinib, Plus a Third Drug for People with BRAF V600-mutant Melanoma." Future Oncology (London, England), vol. 22, no. 9, 2026, p. 995, https://doi.org/10.1080/14796694.2026.2643481.